FIGURE 6.

SR-A-mediated uptake of Pyr-OVA by BMDCs. A, wild-type or SR-A-deficient BMDCs were incubated with 5.0 μg/ml of FITC-conjugated native OVA or AGE-, CM-, CE-, MGO-, and Pyr-OVA for 15 min. B, before incubation with FITC-conjugated native OVA or AGE- or Pyr-OVA, SR-A-deficient BMDCs were treated with BLT-1 (top panels) or anti-CD36 blocking antibodies (bottom panels) for 30 min. C, before incubation with FITC-conjugated native OVA or AGE- or Pyr-OVA, SR-A-deficient BMDCs were treated with mannan or lactose for 30 min. DC uptake of the OVA samples was analyzed by flow cytometry. The gray areas represent cells cultured with medium only. The data are representative of three independent experiments.